|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Division of Hematology/Oncology, Children's
Hospital Medical Center, Cincinnati, OH; and the Division of Pediatric
Oncology, Johns Hopkins Oncology Center, Baltimore, MD.
Activating mutations of c-kit at codon 816 (Asp816) have been implicated in a variety of malignancies,
including acute myeloid leukemia (AML). The mutant c-Kit receptor
confers cytokine-independent survival of leukemia cells and induces
tumorigenicity. Changes in the signal transduction pathways
responsible for Asp816 mutant c-Kit-mediated biologic
effects are largely undefined. The results of this study show that
Asp816 mutant c-Kit induces constitutive activation of
signal transducer and activator of transcription 3 (STAT3) and STAT1,
and up-regulates STAT3 downstream targets, Bcl-xL and
c-myc. The phosphatidylinositol-3-kinase (PI-3K)/Akt
pathway, but not the Ras-mediated mitogen-activated protein
(MAP) kinase pathway, is also constitutively activated by
Asp816 mutant c-Kit. Suppression of STAT3 activation by a
dominant negative molecule in MO7e leukemia cells transduced with
mutant c-kit inhibits stem cell factor (SCF)-independent
survival and proliferation, accompanied by the down-regulation of
Bcl-xL and c-myc. However, activated STAT3 does
not appear to be the sole mediator that is responsible for the
phenotypic changes induced by Asp816 mutant c-Kit, because
expression of constitutively activated STAT3 in MO7e cells does not
completely reconstitute cytokine independence. Activation of other
signaling components by mutant c-Kit, such as those in the PI-3K/Akt
pathway, is demonstrated and may also be needed for the mutant
c-Kit-mediated biologic effects. The investigation of altered signal
transduction pathways and the resulting functional consequences
mediated by Asp816 mutant c-Kit should provide important
information for the characterization of subsets of leukemia and
potential molecular pathways for therapeutic targeting.
(Blood. 2001;97:3559-3567) Signal transducer and activator of transcription
(STAT) proteins are latent transcription factors that are activated by
phosphorylation of a conserved tyrosine residue at their C-terminus,
typically on stimulation of surface receptors by extracellular ligands. Tyrosine phosphorylated STAT molecules in the form of homodimers or
heterodimers subsequently translocate to the nucleus and bind specific
DNA elements, leading to transcriptional activation.1,2 STAT signaling is involved in control of diverse biologic processes regulated by extracellular ligands, including cell proliferation, differentiation, development, and survival. Accumulating evidence has
also demonstrated that abnormal activation of STAT signaling plays a
critical role in oncogenesis. For example, activation of STAT3 or STAT5
induced by certain oncogenes is required for cellular
transformation.3-5 Activated STAT3 by itself is able to
transform fibroblasts from mouse and rat, indicating that STAT3 can
serve as an oncoprotein.6 Constitutive activation of STAT proteins is found in a wide variety of malignancies.7
The proto-oncogene c-kit encodes a cellular receptor, c-Kit,
which is classified as a type III receptor tyrosine kinase
(RTK).8,9 This subfamily of receptors is structurally
characterized by the presence of 5 immunoglobulin (Ig)-like motifs in
the extracellular domain and a cytoplasmic kinase domain interrupted by
a sequence that separates the kinase domain into an adenosine
triphosphate (ATP)-binding region and a phosphotransferase
region.8-10 The ligand for c-Kit is stem cell factor
(SCF), also known as kit ligand, mast cell growth factor, or Steel
factor.11-14 Binding of SCF to c-Kit promotes dimerization
and autophosphorylation of the receptor at specific tyrosine residues.
The phosphorylated receptor then serves as a docking site for the
assembly of multi-subunit complexes that are further activated and
transmit a series of biochemical signals leading to a variety of
cellular responses.10,15 Several pathways have been
implicated in SCF/c-Kit-mediated signal transduction, including the
Ras-Raf-MAP (mitogen-activated protein) kinase cascade,
phosphatidylinositol-3-kinase (PI-3K), Src family kinases, and
STATs.15
Activating mutations in the phosphotransferase region of the kinase
domain of c-kit at codon 814 (Asp814) in mouse
and codon 816 (Asp816) in humans have been identified in
hematopoietic cell lines.16-18 These mutations
promote receptor autophosphorylation without the requirement of
SCF stimulation. In murine experimental systems, Asp814
mutant c-kit can convert cytokine-dependent cell lines to
cytokine independence with associated
tumorigenicity.17-20 Asp816 mutations of
c-kit have been found in some malignancies, including acute
myeloid leukemia (AML),21-23
mastocytosis,24,25 and germ cell
tumors26 However, the molecular mechanisms, especially the
changes in signal transduction pathways, responsible for the functional
effects mediated by Asp816(human)/814(mouse) mutations of
c-kit are not known.
During the process of investigating genes involved in the inhibition of
apoptosis, we have identified a point mutation of c-kit at
codon 816 (D816H) (single-letter amino acid codes) from a revertant of
the cytokine-dependent human AML cell line, MO7e. Another
Asp816 mutation of c-kit (D816N) was
subsequently identified in childhood AML. Functional studies reveal
that these Asp816 c-kit mutants confer MO7e
cells with cytokine-independent survival and a growth advantage, as
well as tumorigenicity and resistance to apoptosis in response to
chemotherapeutic drugs and ionizing radiation.23 In the
present study, we report that activation of STAT3 and its downstream
targets, Bcl-xL and c-myc, is a consequence of
Asp816 mutant c-Kit signaling in leukemia cells. Functional
studies reveal that STAT3 activation is required but not sufficient for mutant c-Kit-mediated cytokine-independent survival and proliferation.
Reagents
Cell lines
Plasmids and cDNAs The complete cDNA open reading frame of wild-type c-kit from MO7e cells was obtained by reverse transcription-polymerase chain reaction (RT-PCR) and cloned into a retroviral plasmid vector containing the neomycin resistance gene, pLNCX (from Dr A. Miller, Fred Hutchinson Cancer Research, Seattle, WA). DNA sequencing showed that the cloned cDNA encodes a GNNK isoform of c-Kit, which is characterized by the
absence of 4 amino acids in the juxtamembrane region of the
extracellular domain due to the alternative messenger RNA (mRNA)
splicing.28,29 D816H or D816N mutant c-kit
plasmids were subsequently constructed by replacement of a 440-bp
fragment from the wild-type cDNA with a region containing the
corresponding point mutations. Wild-type STAT3 cDNA30
tagged with a FLAG epitope and STAT1 cDNA31 were cloned
into a mammalian expression vector containing the hygromycin resistance
gene, pcDNA3.1/Hygro(+) (Invitrogen, Carlsbad, CA). The cDNAs for
dominant-negative STAT3 (Phe substitution at Tyr705, STAT3-YF),32 constitutively activated STAT3 (Cys
substitutions at Ala662 and Asn664, STAT3-C),6 and
dominant-negative STAT1 (Phe substitution at Tyr701,
STAT1-YF)32 were made by PCR-mediated mutagenesis and
cloned into pcDNA3.1/Hygro(+). Wild-type STAT3 and STAT3-C cDNA inserts
containing FLAG epitope were also cloned into the pLNCX vector.
Gene transduction by retrovirus vector Packaging cell line, PA317, was transfected with pLNCX retroviral plasmid containing different cDNA inserts by DOSPER reagents (Roche Molecular Biochemicals, Indianapolis, IN) following the manufacturer's instructions. Supernatants were collected from PA317 cells 48 hours after transfection and passed through 0.45 µm filters. Parental MO7e cells were incubated with individual retroviral supernatant for 5 hours in the presence of SCF and 2 µg/mL polybrene (Sigma). Cells were then centrifuged and resuspended in regular media containing SCF. At 48 hours after infection, 0.8 mg/mL G418 (Gibco-BRL) was added to the cell culture for selecting cells with neomycin resistance.Colony assay MO7e cells stably transduced with D816H mutant c-kit cDNA were subsequently transfected with pcDNA3.1/Hygro(+) vector containing different STAT cDNAs by electroporation using the Gene Pulser apparatus with capacitance extender plus (Biorad, Hercules, CA). Cells (6 × 106) were washed twice with cold phosphate-buffered saline (PBS) and resuspended in 0.8 mL RPMI medium without serum and antibiotics. Cell suspension was mixed with 20 µg plasmid DNA and transferred into a 0.4-cm cuvette. Electroporation was carried out using a combination of 270 V in voltage and 960 µF in capacitance. After electroporation cells were resuspended in 8 mL methylcellulose medium containing 10% FCS without SCF and aliquoted into 3 35-mm tissue culture dishes. Forty-eight hours later, culture dishes were overlaid with 1.5 mL RPMI medium supplemented with hygromycin (0.5 mg/mL, Invitrogen). Fresh hygromycin-containing medium was replaced every 3 days. Three weeks after transfection, colonies that were visually recognizable (consisting of > 100 cells by microscope) were counted both with and without a microscope, the latter used to confirm the identity of colonies as defined. The data presented for each experimental group were the colony numbers that were added from all 3 dishes.Electrophoretic mobility shift assay Cytosolic extracts were prepared as described by Vignais and colleagues33 with modifications. Cells (1 × 107) were resuspended in 100 µL hypotonic buffer (20 mM Hepes/pH 7.9,1 mM EDTA,1 mM EGTA,1 mM DTT, and 0.2% NP-40) with protease inhibitors (Protease Inhibitor Cocktail Tablets, Roche Molecular Biochemicals). After incubation on ice for 15 minutes, cells were lysed by passage through a 28.5-gauge needle. Insoluble debris was removed by a brief centrifugation at 13 000g. Supernatant was recovered and NaCl added to a final concentration of 0.1 M. After centrifugation at 13 000g for 30 minutes, the resulting fractions (cytosolic extracts) with glycerol added to a final concentration of 10%, were used for electrophoretic mobility shift assay (EMSA). Radiolabeled high-affinity SIEm6734 probe was obtained by incubating Klenow enzyme (High Prime, Roche Molecular Biochemicals) and -[32P]dCTP (NEN Life Science
Products, Boston, MA) with the annealed oligonucleotides
5'-GTCGACATTTCCCGTAAATC-3' and 5'-TCGACGATTTACGGGAAATG-3'. Cytosolic
extract (20 µg) was incubated with 1 µg poly (dI-dC)-poly (dI-dC)
(Amersham Pharmacia Biotech, Piscataway, NJ) in binding buffer (50 mM
NaCl, 6 mM Hepes, 1 mM EDTA, 1 mM DTT, and 6% glycerol) for 20 minutes
on ice before adding 30 000 cpm radiolabeled probe. For supershift
assays, nuclear extracts were preincubated with indicated antibody for
40 minutes on ice. Competition was performed with 50 × excess of
unlabeled probe. After binding for 20 minutes at room temperature,
protein-DNA complexes were separated by electrophoresis in 5%
polyacrylamide gels containing 0.5 × TBE buffer with 2.5% glycerol. Gels were dried and subsequently analyzed by autoradiography.
Immunoblotting Total cellular lysates were prepared from cells lysed with modified RIPA2 buffer (20 mM Tris/pH 7.4, 137 mM NaCl, 10% glycerol, 0.1% sodium dodecyl sulfate (SDS), 1% Triton X-100, 2 mM EDTA), supplemented with protease inhibitors and 1 mM DTT. Lysates were centrifuged at 13 000g at 4°C for 20 minutes to pellet cellular debris and the supernatants were collected. Protein (30 µg) from each sample was loaded onto SDS-polyacrylamide gel (SDS-PAGE; acrylamide percentage varying from 8% to 12%) for electrophoresis. Immunoblotting was conducted according to the Research Applications provided by Santa Cruz Biotechnology. Immunoblots were visualized using enhanced chemiluminescence (ECL) reagents (Amersham Pharmacia Biotech) following the manufacturer's instructions.Northern blot analysis Total RNA was isolated from cells by using TRIzol reagent (Gibco-BRL) according to the manufacturer's instructions. Samples of RNA (2 µg) were electrophoresed through 1% agarose gels containing 0.8 M formaldehyde. RNA was transferred to nylon membrane (Micron Separations, Westboro, MA) and hybridized with 32P-labeled probes. The c-myc probe is a human 1.8-kb cDNA insert in pSP65.35 A glyceraldehyde phosphate dehydrogenase (GAPDH) gene probe derived from mouse36 was used for verifying sample loading.Akt kinase assay In vitro Akt kinase assays were carried out by using the Akt Kinase Assay Kit (Cell Signaling Technology, Beverly, MA) according to the manufacturer's instructions. Essentially, Akt protein from MO7e cells was immunoprecipitated with immobilized Akt antibody. The immunoprecipitated Akt protein was resuspended in 40 µL kinase buffer with 1 µg glycogen synthase kinase 3 (GSK-3) fusion protein (substrate for Akt) and 200 µM ATP. The kinase reaction was carried out for 30 minutes at 30°C and terminated with the addition of 20 µL 2 × SDS sample buffer. After a brief centrifugation, the supernatant (20 µL) was loaded onto a 12% SDS-PAGE gel for electrophoresis. The proteins were transferred to the nitrocellulose membrane (Hybond-C Extra, Amersham Pharmacia Biotech) and probed with either anti-phospho-GSK-3 or Akt antibody. Immunoblots were visualized using ECL reagents.Proliferation and apoptosis analysis To evaluate DNA synthesis, MO7e cells (5 × 104/200 µL) were placed in 96-well culture plates in triplicate. After 24 hours for MO7e cells and 48 hours for 293 cells, 1 µCi [3H]thymidine was added to each well and incubated for another 4 hours. Cells were harvested and the amount of incorporated radioactivity was quantitated by liquid-scintillation analysis (Packard Instrument, Meriden, CT). In some situations, cell proliferation was also determined by cell counts.To determine apoptotic cell death, MO7e cells (5 × 104/200 µL) were placed in 96-well culture plates in triplicate in the presence or absence of different concentrations of rhSCF. Twenty-four hours later, the percentage of apoptotic cells was determined by acridine orange staining as previously described.36
Constitutive activation of STAT3 and up-regulation of STAT3 downstream targets are associated with Asp816 mutant c-Kit To determine whether activation of STATs might play a role in mutant c-Kit-mediated biologic effects, we first examined STAT3 and STAT1 activation status by EMSA using a DNA probe derived from the c-fos SIE (sis-inducible element)34 in cells expressing the mutant receptor. Constitutive DNA binding activity of STAT3 homodimers, STAT3/STAT1 heterodimers, and, to a lesser extent, STAT1 homodimers, was present in the cellular extracts from the G50 revertant cell line and from cells transduced with D816H or D816N mutant c-kit (Figure 1, lanes 3, 13, and 15). Constitutive DNA binding activity of STAT3 and STAT1 was also observed in the AML sample from which the D816N mutation of c-kit was identified (Figure 1, lane 17). Although SCF only weakly induced STAT DNA binding activity in MO7e cells expressing wild-type c-Kit, superinduction of activation of STAT3 and STAT1 by SCF was observed in cells expressing the mutant c-Kit receptor (Figure 1, lanes 4, 14, and 16). Similar amounts of c-Kit between wild-type and mutant c-Kit expressing MO7e cells have been demonstrated,23 indicating that the differential activation of STATs in these cells is not due to the difference of receptor expression. SIE-binding proteins were confirmed to be composed of specific STAT dimers, because the protein-DNA complexes disappeared or were significantly diminished following coincubation of cellular extracts with specific antibodies against either STAT3 or STAT1 or both (Figure 1, lanes 6-10).
Consistent with EMSA results, Western blot analysis demonstrated that
the constitutive tyrosine phosphorylation of STAT3 could be further
superinduced by SCF in leukemia cells expressing Asp816
mutant c-kit (Figure 2A, upper
panels). The antibody reactive with tyrosine-phosphorylated STAT3 also
recognized a protein (~85 kd) that showed patterns of activation
similar to that of STAT3 (Figure 2A, upper panels). This protein was
not reactive with an antibody against the internal domain of STAT3
(Figure 2A, lower panels), nor to antibodies against STAT1 or STAT5
(data not shown), indicating that the observed band does not represent
those STAT proteins. Similar patterns of STAT5 tyrosine phosphorylation
were observed in leukemia cells bearing the wild-type and mutant c-Kit receptor in the presence or absence of SCF stimulation (Figure 2B). To
determine that the activation of STAT3 was dependent on the expression
of Asp816 mutant c-Kit, we transfected both D816H mutant
c-kit and STAT3 cDNAs into the human embryonic kidney cell
line, 293, which does not express any endogenous c-Kit receptor. Figure
3 shows that STAT3 activation occurs in
this cell line as a result of cotransfection with both cDNAs, thus
demonstrating the dependence of STAT3 activation on D816H c-Kit
activity.
A number of genes that function to protect against apoptosis or promote
cell cycle progression, such as Bcl-xL and
c-myc, are activated by STAT3.6,37 To determine
whether activation of Bcl-xL or c-myc was
associated with Asp816 mutant c-Kit, MO7e cells stably
transduced with either wild-type or D816H mutant c-kit cDNAs
were analyzed. Western blot analysis showed that Bcl-xL in
MO7e cells transduced with the empty vector or wild-type
c-kit did not appear to be regulated by SCF stimulation (Figure 4A), consistent with the
observations that the protein levels did not notably decline in these
cells following SCF withdrawal (data not shown). However, a
significantly higher level of Bcl-xL expression, which
could be further induced by SCF, was observed in MO7e cells transduced
with D816H mutant c-kit (Figure 4A). A significantly higher
level of c-myc RNA expression was also observed in MO7e
cells expressing the mutant c-Kit receptor (Figure 4B).
These results demonstrate that constitutive activation of STAT3 and up-regulation of STAT3 downstream targets are associated with Asp816 mutant c-Kit, suggesting that the activated components may play an important role in mutant c-Kit-mediated biologic effects in leukemia cells. STAT3 activation is required for SCF-independent survival and proliferation mediated by Asp816 mutant c-Kit To determine whether activation of STAT3 or STAT1 is required for the SCF-independent survival and proliferation mediated by Asp816 mutant c-Kit, MO7e cells, stably transduced with D816H mutant c-kit cDNA, were subsequently transfected with plasmids encoding either the dominant-negative STAT3 or STAT1, as well as various control plasmids. Cytokine-independent survival of D816H mutant bearing MO7e cells was evaluated by colony formation assay, in which the cells were cultivated in the absence of SCF in methylcellulose-based medium containing the appropriate antibiotics. Although D816H c-Kit-expressing cells showed similar colony formation when they were transfected with the empty vector, wild-type STAT3 or STAT1 and dominant-negative STAT1, significantly fewer colonies were observed in cells transfected with dominant-negative STAT3 (Figure 5A). Furthermore, the size of most colonies from cells transfected with dominant-negative STAT3 was remarkably smaller than that observed from cells transfected with other constructs (data not shown), suggesting that the surviving cells had a slower growth rate. To quantitate their proliferative status, individual clones were isolated and expanded in liquid culture in the absence of SCF, followed by counting cell numbers during a period of 4 days. Three clones each from cells transfected with different STAT cDNAs or control vector were evaluated. As shown in Figure 5B, although cells transfected with wild-type STAT3/1 and dominant-negative STAT1 gave rise to a similar growth rate, proliferation was significantly slower in cells transfected with dominant-negative STAT3 (Figure 5B). These results indicate that activation of STAT3, but not STAT1, is required for mutant c-Kit-mediated SCF-independent survival and proliferation in MO7e leukemia cells.
Cloned cells stably transfected with STAT cDNAs or control vector were
further expanded in liquid culture. Cytosolic abstracts from 3 clones
each were isolated and incubated with 32P-labeled SIE
probe, followed by EMSA. Activation of STAT3 and STAT1 by D816H mutant
c-Kit was significantly suppressed in cells transfected with the
corresponding dominant-negative STAT cDNAs, although there was still
considerable DNA binding activity from STAT3/1 heterodimers in
dominant-negative STAT3-transfected cells (Figure
6A). The protein level of
Bcl-xL and the mRNA level of c-myc were also
examined in clones transfected with different STAT cDNAs (Figure 6B,C).
Significant reduction of Bcl-xL and c-myc was
evident only in D816H mutant c-Kit-expressing MO7e cells that were
transfected with dominant-negative STAT3 (Figure 6B,C). Clones within
the same experimental group showed similar patterns of EMSA binding as
well as expression of Bcl-xL and c-myc when compared to tubulin and GAPDH, respectively. The results from representative clones are shown in Figure 6. These results demonstrate that STAT3 activation plays an essential role in mutant c-Kit-induced up-regulation of Bcl-xL and c-myc, which is
likely to be important for mutant c-Kit-mediated biologic effects.
Constitutively activated STAT3 promotes survival of MO7e leukemia cells To further investigate the role of STAT3 activation in SCF-independent survival and proliferation in MO7e leukemia cells, a cDNA plasmid encoding constitutively activated STAT3 (STAT3-C)6 was constructed. Functional analysis of STAT3-C shows that it induces cellular transformation in 293 cells, whereas wild-type STAT3 does not (manuscript in preparation), consistent with the original observations that STAT3-C transforms rat and mouse fibroblasts.6 Parental MO7e cells were transduced with the retroviral particles containing the wild-type STAT3 or STAT3-C tagged with the FLAG epitope. Exogenous STAT3 expression and DNA binding activity from the cytosolic extracts were examined in stable cell lines. Western blot analysis using an anti-FLAG antibody revealed that both wild-type STAT3 and STAT3-C proteins were expressed in the corresponding cell populations (Figure 7A, left panel). However, a greater amount of STAT3-SIE complex, which could be supershifted with anti-FLAG antibody, was observed only in the cytosolic extracts from STAT3-C-transduced MO7e cells (Figure 7A, right panel). Significant DNA binding activity of STAT3-C was still present in the transduced cells even after SCF withdrawal for 12 hours (Figure 7A, right panel). The extent of apoptotic cell death from these cells was determined in the presence or absence of various concentrations of SCF. Although cells transduced with wild-type STAT3 showed a similar percentage of apoptosis compared to cells transduced with the empty vector, significantly less apoptotic cell death was observed in cells transduced with STAT3-C on complete withdrawal of SCF or in the presence of lower SCF concentrations (Figure 7B, left panel). Furthermore, STAT3-C-transduced MO7e cells retained long-term viability in culture at a low concentration (1 ng/mL) of SCF, at which both the empty vector and wild-type STAT3-transduced cells were not able to survive (data not shown). DNA synthesis was also determined by 3H-thymidine incorporation in different transduced cells using the same conditions as described above. Cells transduced with STAT3-C consistently showed more active DNA synthesis than those transduced with the wild-type STAT3 or empty vector in the presence or absence of different concentrations of SCF (Figure 7B, right panel). These results demonstrate that activated STAT3 is able to mediate antiapoptotic and proliferative signals in MO7e cells. However, activated STAT3 by itself is not sufficient to confer SCF-independent survival and proliferation, suggesting that the activation of other signaling pathways by Asp816 mutant c-Kit may be required, together with activated STAT3, for the complete reversal of cytokine dependence of MO7e cells.
To determine whether other major signaling pathways that have been
associated with the regulation of apoptosis might be constitutively activated by mutant c-Kit, we examined PI-3K/Akt activation in MO7e
cells. Akt protein was immunoprecipitated from cells expressing either
wild-type or mutant c-Kit in the presence or absence of SCF, followed
by in vitro kinase assays using recombinant GSK-3, the Akt downstream
target, as substrate. Although Akt kinase activity could be induced by
SCF stimulation in wild-type c-Kit-expressing cells, constitutive
activation of Akt, which could be moderately increased by SCF
stimulation, was observed in cells expressing Asp816 mutant
c-Kit (Figure 8A). In addition, Akt
kinase activity could be suppressed by a PI-3K inhibitor, LY294002
(Figure 8B), indicating that PI-3K is responsible for the Akt
activation in MO7e cells. These results suggest that constitutive
activation of PI-3K/Akt pathway by Asp816 mutant c-Kit may
contribute, together with activated STAT3, to cytokine-independent
survival and proliferation in MO7e cells expressing the mutant
receptor. The induction of apoptosis in MO7e cells expressing either
wild-type or mutant c-Kit by 20 µM LY294002 further supports a
contribution of PI-3K activation to mutant c-Kit-mediated
SCF-independent survival (manuscript in preparation).
D814H c-kit, the mouse mutant corresponding to the human
D816H c-kit, induces constitutive activation of MAP kinases
in a mouse erythroleukemia cell line.18 We examined MAP
kinase activation by Western blot analysis using an antibody
recognizing phosphorylated ERK-1 and ERK-2 (p44 and p42) in MO7e cells
bearing the mutant c-Kit receptor. Basal levels of activation were
comparable between wild-type and mutant c-Kit-expressing cells, but
mutant c-Kit-expressing cells appeared to have moderately higher
levels of MAP kinase phosphorylation than wild-type c-Kit-expressing
cells after SCF stimulation (Figure 9).
The absence of constitutive activation of MAP kinases in MO7e cells
expressing Asp816 mutant c-Kit suggests that MAP kinase
activation does not play a major role in mutant c-Kit-mediated
biologic effects in these leukemia cells.
Mutations of c-kit at codon 816 have been identified in various malignancies, including AML,21,22 mastocytosis,24,38 and germ cell tumors.26 The biologic consequences of these activating mutations, demonstrated mostly by the equivalent mouse c-kit mutations at codon 814, include converting cytokine-dependent cell lines to cytokine independence and inducing tumorigenicity.17-20,39 However, the molecular mechanisms, particularly the changes in the signal transduction pathways, which are responsible for these effects mediated by Asp816(human)/814(mouse) mutations of c-kit, are largely undefined. Data presented in this report demonstrate that constitutive activation of STAT3 and the up-regulation of STAT3 downstream targets are associated with Asp816 mutations of c-kit in leukemia cells. Functional studies using dominant-negative or constitutively activated STAT3 show that STAT3 activation is required for cytokine independent survival and proliferation mediated by Asp816 mutant c-Kit. Multiple pathways have been implicated in SCF/c-Kit-mediated signal transduction, including the Ras-Raf-MAP kinase cascade, PI-3K/Akt, Src family kinases, and JAK/STATs.15 STAT140 and STAT541 have been shown to be activated by SCF in hematopoietic cell lines. STAT3 was reported to be serine, but not tyrosine-phosphorylated by SCF stimulation.42 In contrast to these findings, other studies show that SCF/c-Kit interaction has no measurable effect on STAT family members in other cell lines.43,44 By evaluating either tyrosine phosphorylation or DNA binding activity, we demonstrate that STAT3 and STAT1 are only weakly activated by SCF at its optimal concentration in wild-type c-Kit-expressing MO7e cells. However, when cells are transduced with D816H or D816N mutant c-kit, a significant constitutive activation of STAT3 and STAT1 to levels higher than that in SCF-stimulated cells expressing wild-type c-Kit is observed. Furthermore, activation of these STAT proteins is superinduced by SCF in cells expressing mutant c-Kit. In contrast, the pattern of Ras-mediated MAP kinase activation without SCF stimulation in this system is comparable in cells that express either wild-type or mutant c-Kit. The different observations between these results and others18 regarding MAP kinase activation by mutant c-Kit may reflect the differences of species or leukemia cell lines studied. Constitutive activation of the selective signaling components by Asp816 mutant c-Kit demonstrated in our studies suggests that mutant c-Kit does not simply replace the normal interaction between SCF and the wild-type receptor, but instead has distinct signaling characteristics. This interpretation is supported by 2 other lines of evidence from studies on the mouse Asp814 c-Kit mutants. First, although wild-type c-Kit in the presence of SCF forms dimerized receptors in the extracellular domain, D814Y mutant dimerizes in the cytoplasmic region in the absence of SCF.45 Second, D814V mutant has been shown to possess altered sites of receptor autophosphorylation and shifted specificity for peptide substrates.46 Taken together, our findings and those from others45,46 show that Asp816 mutant c-Kit has certain changes in receptor binding or catalytic properties or both, which selectively activate signal transduction pathways leading to profound phenotypic changes that are distinguishable from the effects of the wild-type receptor. How STAT3 and STAT1 are activated by Asp816 mutant c-Kit is currently unknown. Studies of the platelet-derived growth factor receptor, another type III RTK, have shown that STAT3 and STAT1 can be activated either directly by the receptor47 or in conjunction with other tyrosine kinases, including JAK47 and Src48 kinases. Although STAT1 is reported to associate with c-Kit,40 the physical interactions of c-Kit with other kinases, such as JAK249 and the Src family member, Lyn,50 have also been demonstrated. Future experiments are being directed toward elucidating whether STATs are directly activated by the mutant c-Kit receptor or indirectly activated by other tyrosine kinases. STAT3 has been implicated in protection from apoptosis51-55 and promotion of cell growth.51,54-58 Constitutive activation of STAT3 occurs in a variety of malignancies, including AML.59-63 Our experiments demonstrate that expression of dominant-negative STAT3 in MO7e cells bearing D816H mutant c-Kit significantly inhibits colony formation in methylcellulose, suggesting that STAT3 activation by mutant c-Kit is required for SCF-independent survival in these cells. However, some small colonies were formed from cells transfected with dominant STAT3. We speculate that this could be due to the difference in the extent of STAT3 inhibition by a dominant-negative molecule within the cell population. If STAT3 activation was completely suppressed in a given cell, that cell might not be able to survive, and thus, fewer colonies would be formed. However, if STAT3 activation was incompletely blocked, a cell might survive and proliferate, though with a lower proliferation rate. To support this speculation, our experiments show that surviving clones transfected with dominant-negative STAT3 have little DNA binding activity for STAT3 homodimers, but retain some activity for STAT3/STAT1 heterodimers (Figure 6A). Although a system for inducible expression of dominant-negative STAT3 could also be used in the future to further address the role of inhibition of STAT3 activation in cytokine-independent survival and proliferation mediated by Asp816 mutant c-Kit, these results demonstrate that STAT3 is required for cytokine-independent survival and proliferation. Accumulating evidence suggests that STAT3 inhibits apoptosis and promotes proliferation by regulating the expression of antiapoptosis suppressors, such as Bcl-xL,6,53 and cell cycle modulators, such as c-myc6,37 and cyclins.6,56 Our results show that higher levels of Bcl-xL and c-myc are present in Asp816 mutant c-Kit-expressing MO7e cells compared with that observed in wild-type c-Kit-expressing cells, consistent with the differential activation status of STAT3. Furthermore, expression of Bcl-xL and c-myc is down-regulated by blockade of STAT3 activation in cells expressing mutant c-Kit. These findings imply that Bcl-xL and c-myc are regulated by mutant c-Kit-mediated STAT3 activation and that the up-regulation of these genes may also be involved in SCF-independent survival and proliferation. To address whether activated STAT3 by itself could restore Asp816 mutant c-Kit-induced phenotypic changes, we have expressed a constitutively activated STAT3 molecule6 in parental MO7e cells. In contrast to the results that STAT3 activation is able to reconstitute mutant c-Kit-induced cellular transformation in 293 cells (manuscript in preparation), activated STAT3 by itself is not sufficient to confer SCF-independent survival of MO7e cells. Thus, other signaling pathway(s) that are constitutively activated by mutant c-Kit are likely to be required, together with STAT3 activation, for the complete reversal of cytokine dependence in MO7e cells. This possibility is highlighted by our demonstration that the PI-3K/Akt pathway is also constitutively activated in MO7e cells expressing Asp816 mutant c-Kit and that the blockade of PI-3K activity by a specific inhibitor induces apoptosis in these cells. The PI-3K/Akt pathway has been shown to play a major role in multiple biologic responses mediated by SCF/c-Kit interaction,64-66 including cell survival and proliferation.67,68 In terms of the cooperation between STATs and PI-3K signaling pathway in cellular functions, recent studies have shown that STAT3 acts as an adapter to couple the activation of the interferon receptor by its ligand to the PI-3K pathway,69 and that STAT5 and PI-3K cooperate in the interleukin 3-dependent survival of a bone marrow-derived cell line.70 Our laboratory is currently coexpressing constitutively activated STAT3 and the components of the PI-3K pathway in leukemia cells to further evaluate the role of activation of multiple signaling pathways in Asp816 mutant c-Kit-mediated biologic effects. Activating receptor mutations have been implicated in the pathogenesis of a variety of different forms of cancer, including leukemia.21,22,26,71-74 In the case of AML, although mutations resulting from an internal tandem duplication in the juxtamembrane domain of the Flt3 gene have been reported in a frequency of nearly 20% in AML,71 a recent study has shown that there is also a high frequency of Asp816 mutations of c-kit in AML-M2 with t(8;21) and AML-M4Eo with inv(16): 6 of 15 patients screened had either D816V or D816Y mutation of c-kit.22 The characterization of altered signal transduction pathways and the resulting functional consequences mediated by mutant receptors should provide essential information for the molecular identification of subsets of leukemia and solid tumors as well as the development of nongenotoxic therapies designed to specifically block the function of abnormal receptors and their critical downstream signaling pathways. The results that we have presented demonstrate a mechanism by which a mutant receptor is preferentially linked to STAT3 activation, and, thereby, contributes to leukemia cell survival. These studies may also provide a model system to screen for small molecules that specifically inhibit the aberrant activation of STAT3 by the mutant c-Kit receptor in leukemia cells.
We thank Paul Jubinsky, Hélène Paradis, and Eric Raabe for their helpful discussion and advice, and the Leukemia Research Foundation.
Submitted June 13, 2000; accepted January 18, 2001.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Robert J. Arceci, Johns Hopkins Oncology Center, Division of Pediatric Oncology, Bunting-Blaustein Cancer Research Bldg, 1650 Orleans St, 2M51, Baltimore, MD 21231; e-mail: arcecro{at}jhmi.edu.
1.
Darnell JE Jr.
STATs and gene regulation.
Science.
1997;277:1630-1635 2. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19:2468-2473[CrossRef][Medline] [Order article via Infotrieve].
3.
Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R.
Stat3 activation by Src induces specific gene regulation and is required for cell transformation.
Mol Cell Biol.
1998;18:2545-2552
4.
Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE Jr.
Stat3 activation is required for cellular transformation by v-src.
Mol Cell Biol.
1998;18:2553-2558
5.
de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L.
STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells.
Blood.
1999;94:1108-1112 6. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell. 1999;98:295-303[CrossRef][Medline] [Order article via Infotrieve]. 7. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474-2488[CrossRef][Medline] [Order article via Infotrieve]. 8. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987;6:3341-3351[Medline] [Order article via Infotrieve].
9.
Qiu FH, Ray P, Brown K, et al.
Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family 10. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61:203-212[CrossRef][Medline] [Order article via Infotrieve]. 11. Williams DE, Eisenman J, Baird A, et al. Identification of a ligand for the c-kit proto-oncogene. Cell. 1990;63:167-174[CrossRef][Medline] [Order article via Infotrieve]. 12. Flanagan JG, Leder P. The kit ligand: a cell surface molecule altered in Steel mutant fibroblasts. Cell. 1990;63:185-194[CrossRef][Medline] [Order article via Infotrieve]. 13. Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 1990;63:213-224[CrossRef][Medline] [Order article via Infotrieve]. 14. Huang E, Nocka K, Beier DR, et al. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell. 1990;63:225-233[CrossRef][Medline] [Order article via Infotrieve]. 15. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol. 1999;31:1053-1074[CrossRef][Medline] [Order article via Infotrieve].
16.
Tsujimura T, Furitsu T, Morimoto M, et al.
Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation.
Blood.
1994;83:2619-2626
17.
Piao X, Bernstein A.
A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells.
Blood.
1996;87:3117-3123
18.
Leslie NR, O'Prey J, Bartholomew C, Harrison PR.
An activating mutation in the kit receptor abolishes the stroma requirement for growth of ELM erythroleukemia cells, but does not prevent their differentiation in response to erythropoietin.
Blood.
1998;92:4798-4807
19.
Kitayama H, Kanakura Y, Furitsu T, et al.
Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines.
Blood.
1995;85:790-798 20. Hashimoto K, Tsujimura T, Moriyama Y, et al. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Am J Pathol. 1996;148:189-200[Abstract]. 21. Ashman LK, Ferrao P, Cole SR, Cambareri AC. Effects of mutant c-Kit in early myeloid cells. Leuk Lymphoma. 1999;34:451-461[Medline] [Order article via Infotrieve].
22.
Beghini A, Peterlongo P, Ripamonti CB, et al.
c-kit mutations in core binding factor leukemias [letter].
Blood.
2000;95:726-727 23. Ning Z-Q, Li J, Arceci RJ. Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells. Leuk Lymphoma. In press.
24.
Nagata H, Worobec AS, Oh CK, et al.
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.
Proc Natl Acad Sci U S A.
1995;92:10560-10564
25.
Longley BJ Jr, Metcalfe DD, Tharp M, et al.
Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.
Proc Natl Acad Sci U S A.
1999;96:1609-1614
26.
Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA.
Activating c-kit gene mutations in human germ cell tumors.
Am J Pathol.
1999;154:1643-1647 27. Avanzi G, Lista P, Giovinazzo B, et al. Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br J Haematol. 1988;69:359-366[Medline] [Order article via Infotrieve]. 28. Reith AD, Ellis C, Lyman SD, et al. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J. 1991;10:2451-2459[Medline] [Order article via Infotrieve].
29.
Crosier PS, Ricciardi ST, Hall LR, Vitas MR, Clark SC, Crosier KE.
Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia.
Blood.
1993;82:1151-1158 30. Pietra LD, Bressan A, Pezzotti AR, Serlupi-Crescenzi O. Highly conserved amino-acid sequence between murine STAT3 and a revised human STAT3 sequence. Gene. 1998;213:119-124[CrossRef][Medline] [Order article via Infotrieve].
31.
Schindler C, Fu XY, Improta T, Aebersold R, Darnell JE Jr.
Proteins of transcription factor ISGF-3: one gene encodes the 91- and 84-kDa ISGF-3 proteins that are activated by interferon alpha.
Proc Natl Acad Sci U S A.
1992;89:7836-7839 32. Nakajima K, Yamanaka Y, Nakae K, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 1996;15:3651-3658[Medline] [Order article via Infotrieve]. 33. Vignais ML, Sadowski HB, Watling D, Rogers NC, Gilman M. Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol. 1996;16:1759-1769[Abstract]. 34. Wagner BJ, Hayes TE, Hoban CJ, Cochran BH. The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J. 1990;9:4477-4484[Medline] [Order article via Infotrieve].
35.
Alitalo K, Schwab M, Lin CC, Varmus HE, Bishop JM.
Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma.
Proc Natl Acad Sci U S A.
1983;80:1707-1711 36. Ning Z-Q, Murphy JJ. Calcium ionophore-induced apoptosis of human B cells is preceded by the induced expression of early response genes. Eur J Immunol. 1993;23:3369-3372[Medline] [Order article via Infotrieve].
37.
Kiuchi N, Nakajima K, Ichiba M, et al.
STAT3 is required for the gp130-mediated full activation of the c-myc gene.
J Exp Med.
1999;189:63-73 38. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996;12:312-314[CrossRef][Medline] [Order article via Infotrieve].
39.
Ferrao P, Gonda TJ, Ashman LK.
Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity.
Blood.
1997;90:4539-4552 40. Deberry C, Mou S, Linnekin D. Stat1 associates with c-kit and is activated in response to stem cell factor. Biochem J. 1997;327:73-80. 41. Ryan JJ, Huang H, McReynolds LJ, et al. Stem cell factor activates STAT-5 DNA binding in IL-3-derived bone marrow mast cells. Exp Hematol. 1997;25:357-362[Medline] [Order article via Infotrieve].
42.
Gotoh A, Takahira H, Mantel C, Litz-Jackson S, Boswell HS, Broxmeyer HE.
Steel factor induces serine phosphorylation of Stat3 in human growth factor-dependent myeloid cell lines.
Blood.
1996;88:138-145
43.
O'Farrell AM, Ichihara M, Mui AL, Miyajima A.
Signaling pathways activated in a unique mast cell line where interleukin-3 supports survival and stem cell factor is required for a proliferative response.
Blood.
1996;87:3655-3668
44.
Jacobs-Helber SM, Penta K, Sun Z, Lawson A, Sawyer ST.
Distinct signaling from stem cell factor and erythropoietin in HCD57 cells.
J Biol Chem.
1997;272:6850-6853
45.
Tsujimura T, Hashimoto K, Kitayama H, et al.
Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site.
Blood.
1999;93:1319-1329
46.
Piao X, Paulson R, van der Geer P, Pawson T, Bernstein A.
Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1.
Proc Natl Acad Sci U S A.
1996;93:14665-14669
47.
Vignais ML, Gilman M.
Distinct mechanisms of activation of Stat1 and Stat3 by platelet-derived growth factor receptor in a cell-free system.
Mol Cell Biol.
1999;19:3727-3735 48. Wang YZ, Wharton W, Garcia R, Kraker A, Jove R, Pledger WJ. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity. Oncogene. 2000;19:2075-2085[CrossRef][Medline] [Order article via Infotrieve].
49.
Weiler SR, Mou S, DeBerry CS, et al.
JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor.
Blood.
1996;87:3688-3693
50.
Linnekin D, DeBerry CS, Mou S.
Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells.
J Biol Chem.
1997;272:27450-27455
51.
Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S.
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice.
J Immunol.
1998;161:4652-4660 52. Zushi S, Shinomura Y, Kiyohara T, et al. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer. 1998;78:326-330[CrossRef][Medline] [Order article via Infotrieve]. 53. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-115[CrossRef][Medline] [Order article via Infotrieve].
54.
Niu G, Heller R, Catlett-Falcone R, et al.
Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo.
Cancer Res.
1999;59:5059-5063
55.
Grandis JR, Drenning SD, Zeng Q, et al.
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.
Proc Natl Acad Sci U S A.
2000;97:4227-4232 56. Fukada T, Ohtani T, Yoshida Y, et al. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J. 1998;17:6670-6677[CrossRef][Medline] [Order article via Infotrieve]. 57. Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J Clin Invest. 1998;102:1385-1392[Medline] [Order article via Infotrieve].
58.
Ni Z, Lou W, Leman ES, Gao AC.
Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells.
Cancer Res.
2000;60:1225-1228
59.
Weber-Nordt RM, Egen C, Wehinger J, et al.
Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.
Blood.
1996;88:809-816
60.
Gouilleux-Gruart V, Gouilleux F, Desaint C, et al.
STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients.
Blood.
1996;87:1692-1697 61. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997;159:4720-4728[Abstract].
62.
Xia Z, Baer MR, Block AW, Baumann H, Wetzler M.
Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts.
Cancer Res.
1998;58:3173-3180
63.
Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E.
Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6.
Blood.
2000;95:3765-3770 64. Timokhina I, Kissel H, Stella G, Besmer P. Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J. 1998;17:6250-6262[CrossRef][Medline] [Order article via Infotrieve]. 65. Kissel H, Timokhina I, Hardy MP, et al. Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis and oogenesis without affecting other kit responses. EMBO J. 2000;19:1312-1326[CrossRef][Medline] [Order article via Infotrieve]. 66. Blume-Jensen P, Jiang G, Hyman R, Lee KF, O'Gorman S, Hunter T. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility. Nat Genet. 2000;24:157-162[CrossRef][Medline] [Order article via Infotrieve]. 67. Blume-Jensen P, Janknecht R, Hunter T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol. 1998;8:779-782[CrossRef][Medline] [Order article via Infotrieve].
68.
Feng LX, Ravindranath N, Dym M.
Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia.
J Biol Chem.
2000;275:25572-25576
69.
Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Shi W, Yang CH.
STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor.
Science.
1997;276:1418-1420 70. Rosa Santos SC, Dumon S, Mayeux P, Gisselbrecht S, Gouilleux F. Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line. Oncogene. 2000;19:1164-1172[CrossRef][Medline] [Order article via Infotrieve]. 71. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia. 1997;11:1605-1609[CrossRef][Medline] [Order article via Infotrieve].
72.
Jeffers M, Schmidt L, Nakaigawa N, et al.
Activating mutations for the met tyrosine kinase receptor in human cancer.
Proc Natl Acad Sci U S A.
1997;94:11445-11450
73.
Hirota S, Isozaki K, Moriyama Y, et al.
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
Science.
1998;279:577-580
74.
Hunter MG, Avalos BR.
Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival.
Blood.
2000;95:2132-2137
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  E. Voisset, S. Lopez, P. Dubreuil, and P. De Sepulveda The tyrosine kinase FES is an essential effector of KITD816V proliferation signal Blood, October 1, 2007; 110(7): 2593 - 2599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Munugalavadla, E. C. Sims, J. Borneo, R. J. Chan, and R. Kapur Genetic and pharmacologic evidence implicating the p85{alpha}, but not p85{beta}, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis Blood, September 1, 2007; 110(5): 1612 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pan, A. Quintas-Cardama, H. M. Kantarjian, C. Akin, T. Manshouri, P. Lamb, J. E. Cortes, A. Tefferi, F. J. Giles, and S. Verstovsek EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation Blood, January 1, 2007; 109(1): 315 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Corbacioglu, M. Kilic, M.-A. Westhoff, D. Reinhardt, S. Fulda, and K.-M. Debatin Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin Blood, November 15, 2006; 108(10): 3504 - 3513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Wang, J. Tsukada, T. Higashi, T. Mizobe, A. Matsuura, F. Mouri, N. Sawamukai, C. Ra, and Y. Tanaka Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125. Genes Cells, September 1, 2006; 11(9): 983 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gabillot-Carre, Y. Lepelletier, M. Humbert, P. de Sepuvelda, N. B. Hamouda, J. P. Zappulla, R. Liblau, A. Ribadeau-Dumas, F. Machavoine, S. Letard, et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells Blood, August 1, 2006; 108(3): 1065 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gotlib, C. Berube, J. D. Growney, C.-C. Chen, T. I. George, C. Williams, T. Kajiguchi, J. Ruan, S. L. Lilleberg, J. A. Durocher, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation Blood, October 15, 2005; 106(8): 2865 - 2870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M Metcalfe Axotrophin and leukaemia inhibitory factor (LIF) in transplantation tolerance Phil Trans R Soc B, September 29, 2005; 360(1461): 1687 - 1694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Bowen, M. E. Frew, R. Hills, R. E. Gale, K. Wheatley, M. J. Groves, S. E. Langabeer, P. D. Kottaridis, A. V. Moorman, A. K. Burnett, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years Blood, September 15, 2005; 106(6): 2113 - 2119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Wiesner, J. M. Jones, D. E. Hasz, and D. A. Largaespada Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse Blood, August 1, 2005; 106(3): 1054 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Growney, J. J. Clark, J. Adelsperger, R. Stone, D. Fabbro, J. D. Griffin, and D. G. Gilliland Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412 Blood, July 15, 2005; 106(2): 721 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Corbin, S. Demehri, I. J. Griswold, Y. Wang, C. A. Metcalf III, R. Sundaramoorthi, W. C. Shakespeare, J. Snodgrass, S. Wardwell, D. Dalgarno, et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit Blood, July 1, 2005; 106(1): 227 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. P. Li, J. A. Fletcher, M. C. Heinrich, J. E. Garber, S. E. Sallan, C. Curiel-Lewandrowski, A. Duensing, M. van de Rijn, L. E. Schnipper, and G. D. Demetri Familial Gastrointestinal Stromal Tumor Syndrome: Phenotypic and Molecular Features in a Kindred J. Clin. Oncol., April 20, 2005; 23(12): 2735 - 2743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tefferi Mutant Kit: thwarting the message down below Blood, March 15, 2005; 105(6): 2240 - 2241. [Full Text] [PDF]
|
|
|
|
|
|
T. Jelacic and D. Linnekin PKC{delta} plays opposite roles in growth mediated by wild-type Kit and an oncogenic Kit mutant Blood, March 1, 2005; 105(5): 1923 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lennartsson, T. Jelacic, D. Linnekin, and R. Shivakrupa Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit Stem Cells, January 1, 2005; 23(1): 16 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Corbin, I. J. Griswold, P. La Rosee, K. W. H. Yee, M. C. Heinrich, C. L. Reimer, B. J. Druker, and M. W. N. Deininger Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970 Blood, December 1, 2004; 104(12): 3754 - 3757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Qu, K. Sada, S. Kyo, K. Maeno, S. M. S. Miah, and H. Yamamura Negative regulation of Fc{epsilon}RI-mediated mast cell activation by a ubiquitin-protein ligase Cbl-b Blood, March 1, 2004; 103(5): 1779 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Fumo, C. Akin, D. D. Metcalfe, and L. Neckers 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells Blood, February 1, 2004; 103(3): 1078 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Sternberg and D. G. Gilliland The Role of Signal Transducer and Activator of Transcription Factors in Leukemogenesis J. Clin. Oncol., January 15, 2004; 22(2): 361 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hartmann, M. Artuc, S. E. Baldus, T. K. Zirbes, B. Hermes, J. Thiele, Y. A. Mekori, and B. M. Henz Expression of Bcl-2 and Bcl-xL in Cutaneous and Bone Marrow Lesions of Mastocytosis Am. J. Pathol., September 1, 2003; 163(3): 819 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Meshinchi, D. L. Stirewalt, T. A. Alonzo, Q. Zhang, D. A. Sweetser, W. G. Woods, I. D. Bernstein, R. J. Arceci, and J. P. Radich Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia Blood, August 15, 2003; 102(4): 1474 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Shivakrupa, A. Bernstein, N. Watring, and D. Linnekin Phosphatidylinositol 3'-Kinase Is Required for Growth of Mast Cells Expressing the Kit Catalytic Domain Mutant Cancer Res., August 1, 2003; 63(15): 4412 - 4419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zeuner, F. Pedini, M. Signore, U. Testa, E. Pelosi, C. Peschle, and R. De Maria Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins Blood, July 1, 2003; 102(1): 87 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mizuki, J. Schwable, C. Steur, C. Choudhary, S. Agrawal, B. Sargin, B. Steffen, I. Matsumura, Y. Kanakura, F. D. Bohmer, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations Blood, April 15, 2003; 101(8): 3164 - 3173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hashimoto, I. Matsumura, T. Tsujimura, D.-K. Kim, H. Ogihara, H. Ikeda, S. Ueda, M. Mizuki, H. Sugahara, H. Shibayama, et al. Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation Blood, February 1, 2003; 101(3): 1094 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-I. Park, C. J. Strock, D. W. Ball, and B. D. Nelkin The Ras/Raf/MEK/Extracellular Signal-Regulated Kinase Pathway Induces Autocrine-Paracrine Growth Inhibition via the Leukemia Inhibitory Factor/JAK/STAT Pathway Mol. Cell. Biol., January 15, 2003; 23(2): 543 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Frost, P. T. Ferrao, T. P. Hughes, and L. K. Ashman Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant Mol. Cancer Ther., October 1, 2002; 1(12): 1115 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Attoub, C. Rivat, S. Rodrigues, S. Van Bocxlaer, M. Bedin, E. Bruyneel, C. Louvet, M. Kornprobst, T. Andre, M. Mareel, et al. The c-kit Tyrosine Kinase Inhibitor STI571 for Colorectal Cancer Therapy Cancer Res., September 1, 2002; 62(17): 4879 - 4883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Levis, J. Allebach, K.-F. Tse, R. Zheng, B. R. Baldwin, B. D. Smith, S. Jones-Bolin, B. Ruggeri, C. Dionne, and D. Small A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo Blood, May 13, 2002; 99(11): 3885 - 3891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Miranda, M. Di Virgilio, S. Selleri, G. Zanotti, S. Pagliardini, M. A. Pierotti, and A. Greco Novel Pathogenic Mechanisms of Congenital Insensitivity to Pain with Anhidrosis Genetic Disorder Unveiled by Functional Analysis of Neurotrophic Tyrosine Receptor Kinase Type 1/Nerve Growth Factor Receptor Mutations J. Biol. Chem., February 15, 2002; 277(8): 6455 - 6462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. Appelbaum, J. M. Rowe, J. Radich, and J. E. Dick Acute Myeloid Leukemia Hematology, January 1, 2001; 2001(1): 62 - 86. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
, as shown in the lower panels using the stripped blots
from the upper panels. The lower band observed as part of the doublet
recognized by the antibody against tyrosine-phophorylated STAT3, could
not be definitively identified as STAT3, 1, or 5. Size markers are
shown in kilodaltons. (B) Blots in the upper panels were probed with
the antibody against tyrosine- phosphorylated STAT5. Blots from the
upper panels were stripped and reprobed with the antibody against STAT5
to illustrate the total STAT5 protein, as shown in the lower
panels.
oncogenic activation of v-kit involves deletion of extracellular domain and C terminus.
EMBO J.
1988;7:1003-1011